Galectin Therapeutics (GALT) Amortizatization of Intangibles (2019 - 2024)
Galectin Therapeutics (GALT) posted quarterly Amortizatization of Intangibles of $10000.0 for Q2 2021, up 25.0% year-over-year from $8000.0 in Q2 2020, and little changed quarter-over-quarter from $10000.0 in Q1 2021.
Powered by 
Analysis
Galectin Therapeutics (GALT) Amortizatization of Intangibles (2019 - 2024) Analysis & Trends
Galectin Therapeutics' Amortizatization of Intangibles history runs 3 years deep, the most recent figure standing at $10000.0 for Q2 2021.
- In Q2 2021, Amortizatization of Intangibles rose 25.0% year-over-year to $10000.0; the TTM figure through Jun 2021 stood at $39000.0 (up 14.71% YoY), while the FY2020 annual figure was $36000.0, up 2.86% from the prior year.
- Amortizatization of Intangibles for Q2 2021 stood at $10000.0, roughly flat from $10000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $10000.0 in Q1 2019, with the low at $8000.0 in Q2 2019.
- The 3-year median for Amortizatization of Intangibles is $9000.0 (2019), against an average of $9100.0.
- Peak annual rise in Amortizatization of Intangibles reached 25.0% in 2020, while the deepest fall reached 10.0% in 2020.
- Galectin Therapeutics' Amortizatization of Intangibles stood at $9000.0 in 2019, then changed by 0.0% to $9000.0 in 2020, then rose by 11.11% to $10000.0 in 2021.
- Business Quant data shows GALT's Amortizatization of Intangibles at $10000.0 in Q2 2021, $10000.0 in Q1 2021, and $9000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Galectin Therapeutics | 304.34 Mn | 304.34 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 10,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Jun 30, 2023 | -16,000.00 |
| Mar 31, 2023 | 32,000.00 |
| Dec 31, 2022 | 8,000.00 |
| Sep 30, 2022 | 7,000.00 |
| Jun 30, 2022 | 7,000.00 |
| Mar 31, 2022 | 10,000.00 |
| Dec 31, 2021 | 11,000.00 |
| Sep 30, 2021 | 10,000.00 |
| Jun 30, 2021 | 10,000.00 |
| Mar 31, 2021 | 10,000.00 |
| Dec 31, 2020 | 9,000.00 |
| Sep 30, 2020 | 10,000.00 |
| Jun 30, 2020 | 8,000.00 |
| Mar 31, 2020 | 9,000.00 |